Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLPH NASDAQ:BPTSY NASDAQ:LIPO NASDAQ:PRFX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLPHBellerophon Therapeutics$0.01$0.02$0.01▼$0.02$147K0.7418,907 shsN/ABPTSYBiophytis$0.25$0.35$0.00▼$2.08$586K2.461,154 shsN/ALIPOLipella Pharmaceuticals$0.10$0.07$0.02▼$3.17$462K0.8321,656 shs25,953 shsPRFXPainReform$1.49$2.15$1.28▼$17.95$600K0.77257,050 shs113,769 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLPHBellerophon Therapeutics0.00%0.00%0.00%0.00%0.00%BPTSYBiophytis0.00%0.00%0.00%-44.44%-85.55%LIPOLipella Pharmaceuticals0.00%+11.11%+225.73%-41.18%-96.55%PRFXPainReform0.00%-2.61%-34.65%-48.44%-84.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLPHBellerophon Therapeutics$0.01$0.02$0.01▼$0.02$147K0.7418,907 shsN/ABPTSYBiophytis$0.25$0.35$0.00▼$2.08$586K2.461,154 shsN/ALIPOLipella Pharmaceuticals$0.10$0.07$0.02▼$3.17$462K0.8321,656 shs25,953 shsPRFXPainReform$1.49$2.15$1.28▼$17.95$600K0.77257,050 shs113,769 shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLPHBellerophon Therapeutics0.00%0.00%0.00%0.00%0.00%BPTSYBiophytis0.00%0.00%0.00%-44.44%-85.55%LIPOLipella Pharmaceuticals0.00%+11.11%+225.73%-41.18%-96.55%PRFXPainReform0.00%-2.61%-34.65%-48.44%-84.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLPHBellerophon Therapeutics 0.00N/AN/AN/ABPTSYBiophytis 0.00N/AN/AN/ALIPOLipella Pharmaceuticals 0.00N/AN/AN/APRFXPainReform 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest BLPH, BPTSY, PRFX, and LIPO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026PRFXPainReform Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLPHBellerophon Therapeutics$5.64M0.03N/AN/A$0.27 per share0.04BPTSYBiophytisN/AN/AN/AN/A($16.18) per shareN/ALIPOLipella Pharmaceuticals$536.36K0.86N/AN/A$1.59 per share0.06PRFXPainReform$20K29.80N/AN/A$23.07 per share0.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLPHBellerophon Therapeutics-$19.83M-$0.84N/AN/AN/AN/AN/AN/AN/ABPTSYBiophytis-$18.43MN/AN/AN/AN/AN/AN/AN/AN/ALIPOLipella Pharmaceuticals-$5.02M-$2.42N/AN/AN/A-988.83%-224.08%-172.88%6/3/2026 (Estimated)PRFXPainReform-$5.02M-$736.66N/AN/AN/AN/AN/AN/AN/ALatest BLPH, BPTSY, PRFX, and LIPO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/6/2026Q4 2025PRFXPainReform-$612.00-$0.9850+$611.0150-$0.9850N/AN/A3/26/2026Q4 2025PRFXPainReformN/A-$1.01N/A-$1.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLPHBellerophon TherapeuticsN/AN/AN/AN/AN/ABPTSYBiophytisN/AN/AN/AN/AN/ALIPOLipella PharmaceuticalsN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLPHBellerophon TherapeuticsN/AN/AN/ABPTSYBiophytisN/A0.41N/ALIPOLipella PharmaceuticalsN/A6.216.21PRFXPainReformN/A1.781.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLPHBellerophon Therapeutics10.61%BPTSYBiophytis0.05%LIPOLipella Pharmaceuticals74.31%PRFXPainReform37.28%Insider OwnershipCompanyInsider OwnershipBLPHBellerophon Therapeutics5.20%BPTSYBiophytis3.70%LIPOLipella Pharmaceuticals32.11%PRFXPainReform34.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLPHBellerophon Therapeutics2012.23 million11.60 millionNo DataBPTSYBiophytis302.35 million338,000N/ALIPOLipella Pharmaceuticals44.62 million3.03 millionNot OptionablePRFXPainReform4400,000264,000Not OptionableBLPH, BPTSY, PRFX, and LIPO HeadlinesRecent News About These CompaniesHead-To-Head Comparison: Journey Medical (NASDAQ:DERM) & PainReform (NASDAQ:PRFX)May 24 at 2:18 AM | americanbankingnews.comPRF Technologies Announces FDA Clearance of IND Application for OcuRing™-K Phase II Clinical TrialApril 28, 2026 | globenewswire.comPRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar PlatformsMarch 27, 2026 | globenewswire.comPRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial EngagementsMarch 17, 2026 | globenewswire.comPRF Technologies’ DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable EnergyFebruary 18, 2026 | markets.businessinsider.comPRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable EnergyFebruary 18, 2026 | globenewswire.comPRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial BaseFebruary 11, 2026 | globenewswire.comPRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast AccuracyJanuary 20, 2026 | globenewswire.comPainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy PushJanuary 16, 2026 | benzinga.comPainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy PushJanuary 16, 2026 | benzinga.comPainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy PlatformsJanuary 15, 2026 | finance.yahoo.comPainReform Rebrands as PRF Technologies to Reflect Expansion into Healthcare and AI-Driven EnergyJanuary 15, 2026 | tipranks.comPainReform Ltd. Changes Name to PRF Technologies Ltd.January 15, 2026 | globenewswire.comPainReform’s LayerBio’s Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical StudiesJanuary 12, 2026 | markets.businessinsider.comPainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical StudiesJanuary 12, 2026 | globenewswire.comPainReform (NASDAQ:PRFX) vs. Citius Pharmaceuticals (NASDAQ:CTXR) Financial ComparisonJanuary 10, 2026 | defenseworld.netDPainReform Files Pro Forma Financials Following Majority Acquisition of LayerBioJanuary 7, 2026 | tipranks.comPainReform’s DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A MarketJanuary 5, 2026 | markets.businessinsider.comPainReform Ltd. Launches Smart TDD: Advanced Solar Technical Due Diligence Service to Enhance Asset Performance and Risk AssessmentJanuary 5, 2026 | quiverquant.comQPainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A MarketJanuary 5, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLPH, BPTSY, PRFX, and LIPO Company DescriptionsBellerophon Therapeutics NASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Biophytis NASDAQ:BPTSY$0.25 0.00 (0.00%) As of 05/22/2026Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Lipella Pharmaceuticals NASDAQ:LIPO$0.10 0.00 (0.00%) As of 05/22/2026 02:38 PM EasternLipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.PainReform NASDAQ:PRFX$1.49 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.42 -0.08 (-5.03%) As of 05/22/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
